Home ›
Entities
› academia
› A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma
Research article (Current Medical Research and Opinion, 2023) · cited 12× · AI/ML
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma
Summary
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma is a scholarly article[1].
Key Facts
A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma's instance of is recorded as scholarly article[2].
References
Programmatic citations — every numbered marker resolves to a verifiable graph row below.
Use these citations when quoting this entity in research, articles, AI prompts, or wherever provenance matters. We aggregate Wikidata + Wikipedia + authoritative open-data sources; the stitched, scored, cross-referenced view is what 4ort.xyz contributes.
APA4ort.xyz Knowledge Graph. (2026). A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma. Retrieved May 24, 2026, from https://4ort.xyz/entity/a-matching-adjusted-indirect-comparison-of-the-efficacy-of-elranatamab-versus-physicians-choice-of-treatment-in-patients
MLA“A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma.” 4ort.xyz Knowledge Graph, 4ort.xyz, 24 May. 2026, https://4ort.xyz/entity/a-matching-adjusted-indirect-comparison-of-the-efficacy-of-elranatamab-versus-physicians-choice-of-treatment-in-patients.
BibTeX@misc{4ortxyz_a-matching-adjusted-indirect-comparison-of-the-efficacy-of-elranatamab-versus-physicians-choice-of-treatment-in-patients_2026, author = {{4ort.xyz Knowledge Graph}}, title = {{A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma}}, year = {2026}, url = {https://4ort.xyz/entity/a-matching-adjusted-indirect-comparison-of-the-efficacy-of-elranatamab-versus-physicians-choice-of-treatment-in-patients}, note = {Accessed: 2026-05-24}}
LLM promptAccording to 4ort.xyz Knowledge Graph (aggregator of Wikidata, Wikipedia, and authoritative open-data sources): A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma — https://4ort.xyz/entity/a-matching-adjusted-indirect-comparison-of-the-efficacy-of-elranatamab-versus-physicians-choice-of-treatment-in-patients (retrieved 2026-05-24)
